Respiratory Strong — GOLD 2024
FEV₁/FVC Ratio (Airflow Obstruction)
Interprets spirometry FEV₁/FVC ratio to classify airflow obstruction severity per GOLD criteria.
References
- GOLD Global Strategy for COPD. 2024.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Azithromycin (COPD Exacerbation Prophylaxis) · Macrolide antibiotic (anti-inflammatory / prophylactic)
- Doxycycline (COPD Exacerbation / CAP) · Oral tetracycline antibiotic
- Co-amoxiclav 625mg (COPD Exacerbation / CAP) · Beta-lactam / Beta-lactamase inhibitor combination antibiotic
- Fluticasone Furoate / Vilanterol · ICS/LABA — Asthma / COPD
- Beclometasone / Formoterol · ICS/LABA — Asthma / COPD
- Fluticasone Furoate / Umeclidinium / Vilanterol · Triple Therapy ICS/LAMA/LABA — COPD
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
- Community-Acquired Pneumonia (CURB-65) · BTS 2009 / NICE NG138
- Acute Pulmonary Embolism · BTS 2003 / ESC 2019
- Pleural Effusion Assessment · BTS 2010
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.